Welcome to our dedicated page for Maxcyte news (Ticker: MXCT), a resource for investors and traders seeking the latest updates and insights on Maxcyte stock.
MaxCyte, Inc. (NASDAQ: MXCT) is a cell-engineering focused company whose news flow centers on its enabling platform technologies, financial performance and strategic partnerships in next-generation cell-based therapeutics. As a commercial cell engineering company, MaxCyte regularly issues updates on its core business revenue, Strategic Platform License (SPL) program-related revenue and total cash, cash equivalents and investments, giving investors insight into how its platform is being adopted and how its financial profile is evolving.
News about MaxCyte often includes quarterly and annual financial results, preliminary earnings updates and revised guidance ranges for core revenue and SPL program-related revenue. These releases typically discuss core revenue from instruments, processing assemblies and consumables, licenses, assay services and other categories, as well as program-related revenue tied to SPL milestones and royalties. Management commentary in these announcements frequently addresses operating environment conditions, cost structure, operational restructuring and the company’s path toward profitability.
Another key category of MXCT news involves new and expanded SPL agreements with biotechnology partners. Recent press releases have highlighted SPLs with companies such as Adicet Bio and Moonlight Bio, where MaxCyte’s Flow Electroporation technology and ExPERT platform are being deployed to support scalable development and manufacturing of gene-edited T cell therapies and gamma delta T cell programs. These partnership updates help illustrate how MaxCyte’s platform is used across different cell therapy pipelines.
Corporate developments also feature in the company’s news stream. Examples include the announcement of an operational restructuring and workforce reduction plan designed to reduce costs and align resources with strategic priorities, as well as leadership transitions such as planned changes in the chief financial officer role. For investors and industry observers, following MXCT news can provide ongoing context on MaxCyte’s business performance, partner activity and strategic decisions within the cell and gene therapy ecosystem.
MaxCyte (Nasdaq: MXCT) provided preliminary unaudited results for the quarter and year ended December 31, 2025. Q4 core revenue is expected to be $6.6M–$6.7M and FY2025 core revenue is expected to be $29.5M–$29.6M. SPL program revenue is expected to be $0.4M–$0.6M for Q4 and $3.3M–$3.5M for FY2025. Cash, cash equivalents, and investments are expected to be approximately $155.6M as of December 31, 2025. Management described 2025 as challenging but said core revenue was in line with guidance, noted cost-structure improvements and program rationalization, and stated an expectation to return to revenue growth in H2 2026. Final audited results are expected in March 2026.
Cellares announced Ali Soleymannezhad as Chief Commercial Officer to lead global commercial expansion and prepare the company for a future IPO.
The appointment follows five global manufacturing agreements with partners including Bristol Myers Squibb and Kite, the FDA’s first Advanced Manufacturing Technology (AMT) designation for the Cell Shuttle platform, and plans to support multiple clinical trials in 2026. Soleymannezhad brings over two decades of commercialization experience from MaxCyte (NASDAQ: MXCT) and Tosoh Bioscience and will oversee enterprise sales, business development, and licensing for Cellares’ IDMO Smart Factories across the US, Europe, and Japan.
MaxCyte (Nasdaq: MXCT) announced that Chief Financial Officer Douglas Swirsky will transition from his CFO role in the first half of 2026. Mr. Swirsky will remain CFO until a successor is appointed, will support a structured successor search, and will continue in an advisory capacity after the transition to support strategic initiatives and continuity.
The company and Mr. Swirsky say the planned, orderly handoff is not expected to affect operations, results, financial reporting cadence, or strategic priorities.
MaxCyte (NASDAQ: MXCT) reported third quarter 2025 results and reiterated full-year 2025 guidance on Nov 12, 2025. Total revenue was $6.8M in Q3 2025, down 16% year-over-year; core revenue was $6.4M, down 21% YoY. Gross profit was $5.2M (77% gross margin); non-GAAP adjusted gross margin was 81% versus 85% in Q3 2024. Q3 net loss was $12.4M; adjusted EBITDA loss improved to $10.0M from $13.0M. Installed instrument base rose to 830. Management reiterated 2025 guidance: core revenue flat to -10% and ~$5M SPL program revenue; expected year-end cash of $152M–$155M.
MaxCyte (NASDAQ: MXCT) reported preliminary third-quarter 2025 results and reiterated full-year 2025 revenue guidance on Nov 5, 2025. Q3 total revenue was $6.8M with core revenue $6.4M and SPL program-related revenue $0.4M. Gross margin was $5.2M (77%), with a non-GAAP adjusted gross margin of 81% excluding SPL and inventory reserves. Cash, cash equivalents and investments totaled $158.0M at September 30, 2025. The company is delaying the formal Q3 release and call to complete impairment testing of goodwill and long-lived assets; guidance sees year-end cash of $152M–$155M and SPL revenue ~$5M for 2025.
MaxCyte (NASDAQ: MXCT) will report third quarter 2025 financial results after the U.S. market close on Wednesday, November 5, 2025.
Company management will host an earnings conference call at 4:30 p.m. Eastern Time the same day. Investors must register online in advance to join the call, and a live and archived webcast will be available in the Events section of MaxCyte's investor website at https://investors.maxcyte.com/.
MaxCyte (Nasdaq: MXCT) signed a Strategic Platform License (SPL) with Moonlight Bio on Oct 6, 2025 to support development and scalable manufacturing of Moonlight's engineered T cell therapies for solid tumors. Moonlight gains non-exclusive research, clinical, and commercial rights to MaxCyte's Flow Electroporation® technology and ExPERT™ platform. MaxCyte will receive annual licensing fees and program-related revenue while Moonlight will use GMP-ready electroporation and regulatory support to build clinical manufacturing processes.
MaxCyte (NASDAQ:MXCT), a cell-engineering platform technology company, has announced a significant operational restructuring to optimize costs and accelerate profitability. The plan includes a 34% reduction in global workforce, expected to generate $13.6 million in annual savings.
The company reiterated its 2025 guidance, expecting core revenue to be flat to down 10% compared to 2024, with $5 million in SPL program-related revenue. MaxCyte projects to maintain at least $155 million in cash, cash equivalents, and investments by year-end.
MaxCyte (NASDAQ: MXCT) reported Q2 2025 financial results with mixed performance. The company's core business revenue reached $8.2 million, up 8% year-over-year, while total revenue decreased 18% to $8.5 million due to lower Strategic Platform License (SPL) Program-related revenue. The company added two new SPL clients, bringing the total to 31 agreements.
Key metrics show an installed base of 814 instruments and 42% of core revenue generated by SPL clients. The company updated its 2025 guidance, projecting core revenue to be flat to 10% down compared to 2024, with SPL Program-related revenue expected at approximately $5 million. MaxCyte anticipates ending 2025 with at least $155 million in cash and investments.
MaxCyte (NASDAQ:MXCT) has signed a strategic platform license agreement with Adicet Bio for the use of MaxCyte's Flow Electroporation® technology and ExPERT™ platform. The non-exclusive license grants Adicet Bio research, clinical, and commercial rights to support their gamma delta T cell therapy gene edited programs.
Under the agreement, MaxCyte will receive platform licensing fees and program-related revenue. Adicet Bio will utilize MaxCyte's technology to enhance their proprietary manufacturing process for allogeneic gamma delta T cell therapies, aimed at treating cancer and autoimmune diseases.
The collaboration leverages MaxCyte's ExPERT™ platform, which provides high transfection efficiency, cell viability, and seamless scalability for complex cell engineering applications.
FAQ
What is the current stock price of Maxcyte (MXCT)?
What is the market cap of Maxcyte (MXCT)?
